Oculis Holding AG announced that the final patient visit has been completed in the DIAMOND phase 3 program assessing OCS-01, ...
Starr, MD, FACS, highlights diagnostic gaps in dry eye, emphasizing neuropathic corneal pain and reviewing emerging therapies ...
Propensity-matched analyses showed smokers had significantly higher risk across all studied ocular outcomes over 10 years, ...
Self-reported hearing impairment reduced the likelihood of achieving clinically meaningful functional improvement after ...
The early results from a phase II study on the use of the topotecan episcleral chemoplaque (Targeted Therapy Technologies LLC ...
Motugivatrep introduces first-in-class topical TRPV1 antagonism for DED, targeting corneal nociceptor-driven discomfort ...
Gabriel discusses a robotic femtosecond laser platform for LASIK, focusing on flap accuracy, stromal bed precision, and the ...
New 52-week analyses from the phase 3 SOL-1 trial suggest that the investigational intravitreal therapy AXPAXLI (OTX-TKI) may ...
Glaukos Corporation announced that the US Centers for Medicare and Medicaid Services (CMS) has assigned a permanent ...
Quesada discusses a robotic femtosecond laser platform for LASIK, focusing on flap accuracy, stromal bed precision, and the role of integrated OCT imaging.
Uncorrected acuity at 36 months showed continuous range: monocular 20/20 distance and intermediate, 20/27 near; binocular ...
The FDA’s decision to extend the labeled duration of faricimab use in RVO beyond 6 months primarily reflects accumulated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results